Cancer Risk Assessment in Individuals with Hidradenitis Suppurativa: A Comprehensive Review and Meta-Analysis - Report - MDSpire

Cancer Risk Assessment in Individuals with Hidradenitis Suppurativa: A Comprehensive Review and Meta-Analysis

  • By

  • Daniel Isufi

  • Mikkel Bak Jensen

  • Nikolai Loft

  • Rune Kjærsgaard Andersen

  • March 11, 2026

  • 0 min

Share

Clinical Report: Cancer Risk Assessment in Individuals with Hidradenitis Suppurativa

Overview

This meta-analysis reveals that individuals with hidradenitis suppurativa (HS) have a significantly elevated overall cancer risk, particularly for gastrointestinal, head and neck, hematological, and respiratory cancers. The findings underscore the need for further studies to adjust for confounding factors such as smoking and BMI.

Background

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that can severely impact quality of life and is associated with various comorbidities. Understanding the cancer risk in HS patients is crucial, as chronic inflammation may predispose them to malignancies. Previous studies have shown inconsistent results regarding cancer incidence in HS, necessitating a comprehensive review to clarify these risks.

Data Highlights

{'hematological_cancers': "Provide specific odds ratio or clarify the term 'Elevated Risk'.", 'respiratory_cancers': "Provide specific odds ratio or clarify the term 'Elevated Risk'."}

Key Findings

  • Patients with HS have a significantly elevated risk of overall cancer compared to the general population.
  • Specific cancers with increased risk include gastrointestinal, head and neck, hematological, and respiratory cancers.
  • Hodgkin and non-Hodgkin lymphoma risks are also elevated in HS patients.
  • Confounding factors such as smoking, BMI, and alcohol intake need to be accounted for in future studies.
  • Current evidence suggests a modest overall elevation in cancer risk among HS patients.

Clinical Implications

Healthcare providers should be vigilant in monitoring HS patients for potential malignancies, particularly in the gastrointestinal and lymphatic systems. Regular clinical examinations and biopsies of atypical lesions are recommended to catch any malignant transformations early.

Conclusion

The findings of this meta-analysis highlight a significant cancer risk in patients with hidradenitis suppurativa, emphasizing the importance of ongoing surveillance and further research to clarify the underlying mechanisms and risk factors.

References

  1. Conexiant, Conexiant, 2023 -- HS Linked to Higher Cancer Risk
  2. Contact Lens Spectrum, Contact Lens Spectrum, 2022 -- ONLINE PHOTO DIAGNOSIS
  3. Elevated Incidence of Hidradenitis Suppurativa Among Individuals with Perianal Fistulas, Springer, 2019 -- Elevated Incidence of Hidradenitis Suppurativa
  4. PMC, Risk of Cancer in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-analysis, 2023
  5. Karger Publishers, Swiss S1 Guidelines for the Management of Hidradenitis Suppurativa, 2025
  6. Clinical Rheumatology — Identifying Risk Factors Associated with Primary Sjögren’s Syndrome: A Comprehensive Review and Meta-Analysis
  7. Risk of Cancer in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-analysis - PMC
  8. Swiss S1 Guidelines for the Management of Hidradenitis Suppurativa | Dermatology | Karger Publishers
  9. Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis | Dermatology | JAMA Dermatology | JAMA Network

Original Source(s)

Related Content